Penetrium: A Breakthrough in Overcoming Cold Tumors and Metastatic Cancer
/0 Comments/in Preclinical Research/by MaxPioglitazone: Diabetes Drug Shows Promise for Treating Prostate Cancer
/0 Comments/in Drug repurposing, Preclinical Research/by MaxUPDATE: JANX007 Starts Phase 1b Expansion Studies
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNTS071 to Target p53 Y220C Mutation in Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 18/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! As you probably know, last week was the week of AACR 2025 (American Association for Cancer Research) and AUA 2025 (American Urological Association), so we have a very packed newsletter! Enjoy the read! Stay strong and fight on! As […]
Transdermal Estradiol: A Cost-Saving, Quality-of-Life Boost for Prostate Cancer Therapy
/0 Comments/in Review/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Newsletter 32/2025 August 10, 2025
- New Bacterial Therapy Destroys Tumors in Immunocompromised Animal Models August 9, 2025
- Phase 2 trial: Tarlatamab for Neuroendocrine Prostate Cancer (NEPC) August 8, 2025
- Phase Ib/II Study of TYK-00540 Combined With Enzalutamide in mCRPC August 8, 2025